|
|
Profile
|
Delegates :
Masaki Yamada |
|
Incorporated :
August 22 , 2022 |
Paid in Capital :
650 Million yen |
Employees :
11 人 |
Address :
8-35-1, Sakuragaoka, Kagoshima, 890-8544 Japan Graduate School of Medical & Dental Sciences, Kagoshima Univ KAGOSHIMA
〒8908544
|
TEL/FAX :
099-296-8110 / |
URL：
https://www.survbiopharma.co.jp/en/ |
Attachment :
|
Mission/Background :
Surv BioPharma is a Kagoshima University-accredited bioventure company established to commercialize therapeutic viruses developed by Prof. Kosai of Kagoshima University.
We have created a novel OV (“Type 1”) that only attacks cancer cells, and are now working to file a new drug application (NDA) in 2025 for the treatment of bone and soft tissue tumors for which no therapeutic drugs are currently available. In addition to the Type 1 OV, we also possess several promising drug candidates.
|
|
Technology & Business
|
Our founder Professor Kosai developed a proprietary technology platform for constructing m-CRAs with various tissue- and tumor-specific replication properties. He first removed the endogenous promoter required for viral replication from the human adenovirus backbone and then inserted tissue- and-tumor-specific promoters at its appropriate positions.
Despite attempts in the 1990s to develop treatments using non-replicating (“replication-defective”) adenoviral vectors, the resulting therapeutic viruses did not elicit adequate response due to their limited ability of propagation. Replication-regulated adenoviral vectors subsequently emerged but only a single factor was used to support/regulate its replication, resulting in inadequate cancer cell specificity.
Using our proprietary technology, Surv BioPharma has succeeded in enhancing cancer cell specificity by precisely regulating viral replication with multiple cancer-specific factors.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Oncolytic Virus （Type1） Surv.m-CRA-1
|
Phase2
|
Bone tumors in Japan. Apply for orphan drug designation
|
Seeking licensee in/outside Japan
|
Oncolytic Virus （Type2） Surv.m-CRA-2-G
|
Preclinical
|
Solid cancers (Invasive/metastatic)
|
Seeking licensee in/outside Japan
|
Oncolytic Virus （Type2） Surv.m-CRA-2-IC
|
Preclinical
|
Solid cancers (Invasive/metastatic)
|
Seeking licensee in/outside Japan
|
In vivo gene therapy（Adenovirus Type）
|
Preclinical
|
hepatic disease and diabetes mellitus
|
Seeking licensee in/outside Japan
|
In vivo gene therapy（Adeno-associated virus (AAV) Type）
|
Preclinical
|
hepatic disease and diabetes mellitus
|
Seeking licensee in/outside Japan
|
|
Highlights
|
Our first drug candidate, “Surv.m-CRA-1” (survivin-responsive m-CRA), was developed in compliance with GMP, GLP and other global regulatory standards and in 2020, underwent an investigator-initiated Phase I (“P1”) first-in-human clinical study. Due to the high levels of safety & efficacy data obtained from the P1 study, a P2 proof-of-concept (POC) study is currently underway in 20 patients to confirm the effects of Surv.m-CRA-1 as a therapeutic virus.
|
|
Hot news
|
The Surv.m-CRA-IC project has been selected for AMED's “Seeds F”. The project will receive up to 70 million yen in R&D funding for up to five years (90 million yen for stage-gate projects from the third year onward).
|
|
Alliance strategy
|
To achieve our goal, we recognize the need to partner with pharmaceutical companies who share our vision. We are seeking partnerships with companies with proven capabilities in late-stage clinical development, manufacturing and marketing to leverage our synergies to deliver therapeutic drugs to patients in need expediently. We welcome expressions of interest in licensing opportunities within the orphan disease field.
|
|
|